What smart money is saying about Edgewise Therapeutics
2 funds in our archive have pitched Edgewise Therapeutics, most recently Artisan Non US Small Mid Growth Strategy in June 2025.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Get an email when a fund buys, sells or pitches it
Position history
Between Q4 2024 and Q2 2025, 1 fund letter reported a position in Edgewise Therapeutics, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2025 | 1 | 0 | 0 | 1 |
| Q4 2024 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position
- June 2025
“Edgewise Therapeutics is an example of a clinical-stage biotechnology company that signifies the type of risk-reward we like in such investments.”
Edgewise Therapeutics
Fund coverage · 2 theses
Edgewise Therapeutics is a clinical-stage biotechnology company with significant risk-reward potential, developing innovative treatments for muscular diseases and targeting the multibillion-dollar opportunity in hypertrophic cardiomyopathy and diastolic heart failure.
Read the full thesis- Baron Health Care FundDecember 2024
Edgewise Therapeutics, Inc. is developing innovative drugs for muscle disorders, including sevasetment for Becker’s and Duchenne muscular dystrophies, and EDG-7500 for hypertrophic cardiomyopathy, showing promising early efficacy and potential market impact.
Read the full thesis
Read every full thesis on Edgewise Therapeutics
Read all 2 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→